How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

63,564 results for

Type 1 Diabetes Mellitus

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. Correlation between gene polymorphism in angiotensin II type 1 receptor and type 2 diabetes mellitus complicated by hypertension in a population of Inner Mongolia. Full Text available with Trip Pro

Correlation between gene polymorphism in angiotensin II type 1 receptor and type 2 diabetes mellitus complicated by hypertension in a population of Inner Mongolia. The role of angiotensin II type 1 receptor (AT1R) as a key player in type 2 diabetes mellitus (T2DM) complicated with hypertension remains controversial. The present case-control study systematically investigated the association between gene the correct variation type in the angiotensin II type 1 receptor (AT1R) gene and type 2 (...) ). Genomic DNA was extracted from samples from 202 type 2 diabetic patients with hypertension and 216 type 2 diabetic patients without hypertension.Non-conditional regression analysis showed that in comparison with the TT genotype, the presence of the CC genotype for the T573 site of the AT1R gene increased the risk for diabetes mellitus complicated with hypertension by 3.219-fold (OR = 3.219, 95% CI: 1.042-9.941, P = 0.042). The results from multivariate linear regression analysis suggested the rs5182

2020 BMC Medical Genetics

62. Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicenter study: The L Full Text available with Trip Pro

Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicenter study: The L To assess efficacy and safety of 26-week treatment with insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared with insulin glargine U100 (iGlar) in Japanese patients with type 2 diabetes mellitus (T2DM) inadequately (...) controlled on oral antidiabetic drugs (OADs).This phase 3, multicenter, open label, 1:1 randomized, parallel-group study compared efficacy of iGlarLixi and iGlar in patients with T2DM, HbA1c of ≥7.5% to ≤9.5% and fasting plasma glucose ≤10.0 mmol/L (180 mg/dL). The primary endpoint was change in HbA1c from baseline to week 26.Patients were randomized to iGlarLixi (n = 260) or iGlar (n = 261) (mean age 59.7 years, baseline BMI 26.04 kg/m2 , and HbA1c 8.04% [64.4 mmol/mol]). HbA1c reduction

2020 obesity & metabolism

63. Dapagliflozin with insulin for treating type 1 diabetes

of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 5 of 242 2 Information about dapagliflozin Information about dapagliflozin Mark Marketing eting authorisation authorisation Dapagliflozin (Forxiga, AstraZeneca) is indicated for the treatment of 'type 1 diabetes mellitus as an adjunct to insulin in patients with a BMI = 27 kg/m2, when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy' . Dapagliflozin should not be started in people (...) Dapagliflozin with insulin for treating type 1 diabetes Dapagliflozin with insulin for treating Dapagliflozin with insulin for treating type 1 diabetes type 1 diabetes T echnology appraisal guidance Published: 28 August 2019 www.nice.org.uk/guidance/ta597 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE, arrived

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

64. Metformin Improves Insulin Sensitivity and Vascular Health in Youth With Type 1 Diabetes Mellitus Full Text available with Trip Pro

Metformin Improves Insulin Sensitivity and Vascular Health in Youth With Type 1 Diabetes Mellitus Cardiovascular disease is the leading cause of mortality in type 1 diabetes mellitus (T1DM) and relates strongly to insulin resistance (IR). Lean and obese adolescents with T1DM have marked IR. Metformin improves surrogate markers of IR in T1DM, but its effect on directly measured IR and vascular health in youth with T1DM is unclear. We hypothesized that adolescents with T1DM have impaired vascular (...) , fasting laboratories after overnight glycemic control, and insulin sensitivity by hyperinsulinemic-euglycemic clamp (glucose infusion rate/insulin). Adolescents with T1DM were randomized 1:1 to 3 months of 2000 mg metformin or placebo daily, after which baseline measures were repeated.Forty-eight adolescents with T1DM who were 12 to 21 years of age (40% body mass index [BMI] ≥90th percentile; 56% female) and 24 nondiabetic control participants of similar age, BMI, and sex distribution were enrolled

2019 EvidenceUpdates

65. Management of adult patients with type 1 diabetes mellitus in Africa: A post-hoc cohort analysis of 12 African countries participating in the International Diabetes Management Practices Study (Wave 7). Full Text available with Trip Pro

Management of adult patients with type 1 diabetes mellitus in Africa: A post-hoc cohort analysis of 12 African countries participating in the International Diabetes Management Practices Study (Wave 7). There is a paucity of information on real world management of African adult patients with type 1 diabetes mellitus (T1DM). We aimed to describe a cohort of African adults with T1DM.The International Diabetes Management Practices Study is an observational survey conducted from 2005 to 2017. Data (...) %. A total of 196 (24.9%) reported being hospitalized in the preceding year, with the most common reasons being diabetic ketoacidosis (58.1%, 93/160) and hypoglycaemia (31.1%; 52/167). Over half of the patients (55.4%) stated that the cost of test strips limited regular glycemic monitoring; a minority of patients (15%, 120/788) received structured diabetes education. Predictors of HbA1c <7% included patients receiving diabetes education (odds ratio [OR] [95% confidence interval, CI] = 2.707 [1.157-6.335

2020 Medicine

66. Empaglifozin linagliptin fixed-dose combination (Glyxambi) - type 2 diabetes mellitus:

Empaglifozin linagliptin fixed-dose combination (Glyxambi) - type 2 diabetes mellitus: Published 12 August 2019 1 Product Update: empagliflozin plus linagliptin 10mg/5mg, 25mg/5mg film-coated tablets (Glyxambi ® ) SMC No. (1236/17) Boehringer Ingelheim Ltd. 07 April 2017 (Issued July 2019) The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice (...) is summarised as follows: ADVICE: following an abbreviated submission empagliflozin/linagliptin (Glyxambi ® ) is accepted for restricted use within NHS Scotland. Indication under review: in adults aged 18 years and older with type 2 diabetes mellitus: ? To improve glycaemic control when metformin and/or sulphonylurea (SU) and one of the monocomponents of Glyxambi ® do not provide adequate glycaemic control ? When already being treated with the free combination of empagliflozin and linagliptin SMC

2019 Scottish Medicines Consortium

67. Ertugliflozin (Steglatro) - type 2 diabetes mellitus

Ertugliflozin (Steglatro) - type 2 diabetes mellitus 1 Published 14 January 2019 1 SMC2102 ertugliflozin 5mg, 15mg film-coated tablet (Steglatro®) Merck Sharp & Dohme 7 December 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission ertugliflozin (Steglatro ® ) is accepted (...) comparator. The target populations were: Adult patients with uncontrolled type 2 diabetes mellitus having previously received one of the following interventions: ? population 1 (monotherapy): diet and exercise, no background pharmacological therapy (eleven studies, including VERTIS MONO) ? population 2 (dual therapy): metformin alone (eight studies, including VERTIS MET and VERTIS FACTORIAL) ? population 3 (triple therapy): metformin plus a DPP-4 inhibitor (five studies, including VERTIS SITA2

2019 Scottish Medicines Consortium

68. Semaglutide (Ozempic) - the treatment of adults with insufficiently controlled type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise

Semaglutide (Ozempic) - the treatment of adults with insufficiently controlled type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise 1 Published 14 January 2019 1 SMC2092 semaglutide 0.25mg, 0.5mg and 1mg solution for injection in pre-filled pen (Ozempic®) Novo Nordisk Ltd. 9 November 2018 (Issued 7 December 2018) The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its (...) use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission semaglutide (Ozempic ® ) is accepted for restricted use within NHSScotland. Indication under review: the treatment of adults with insufficiently controlled type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise: ? As monotherapy when metformin is considered inappropriate due to intolerance or contraindications ? In addition to other medicinal products for the treatment of diabetes. SMC

2019 Scottish Medicines Consortium

69. Type 2 Diabetes Mellitus and Heart Failure Full Text available with Trip Pro

-1 receptor agonists if no recent HF decompensation) could be considered, but use with caution; may require dose adjustment DM indicates diabetes mellitus; DPP-4, dipeptidyl peptidase-4; EF, ejection fraction; eGFR, estimated glomerular filtration rate; GLP-1, glucagon-like peptide-1; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; SGLT-2, sodium glucose cotransporter type 2; and TZDs, thiazolidinedione drugs. Figure 3 (...) with either GLP-1 receptor agonists or DPP-4 inhibitors compared with other glucose-lowering therapies. Additional data are still needed to determine whether there is, in fact, a higher risk of HF with DPP-4 inhibitors in individuals with DM. Some additional information could come from the CARMELINA trial (Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus; URL: . Unique identifier: NCT01897532), which compares linagliptin versus placebo

2019 American Heart Association

70. Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes?

inhibitors, SGLT-2 inhibitors, and SGLT-1/SGLT-2 inhibitors may be considered experimental drugs being tested for adjunctive therapy in T1D adult patients. As such, their place in therapy in the management of T1D still needs to be defined. Background Diabetes mellitus is a metabolic disorder that results from defects in insulin secretion, insulin action, or both. 1 There are two major categories of diabetes. Type 1 diabetes (T1D) is characterized by severe impairment or an absolute deficiency of insulin (...) Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes? Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes? | CADTH.ca CADTH Document Viewer Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes? Table of Contents Search this document Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes? January 2018 Summary There are two major

2018 CADTH - Issues in Emerging Health Technologies

71. Illness perception of adolescents with well-controlled type 1 diabetes mellitus Full Text available with Trip Pro

Illness perception of adolescents with well-controlled type 1 diabetes mellitus In this study, to explore the illness perceptions of adolescents with well-controlled type 1 diabetes mellitus in South Africa, semi-structured interviews were conducted with nine, purposively selected adolescents (mean = 13.9 years; median = 12). Themes that emerged from the thematic analysis include the following: accepting diabetes and the diabetes care plan as part of their lives; viewing diabetes as manageable (...) and as their responsibility; and the important role of gaining information on diabetes and diabetes management. These perceptions contributed to adherence to diabetes care plans and should be explored and developed among adolescents with type 1 diabetes mellitus to improve their diabetes management.

2018 Health psychology open

72. A Practical Approach to the Management of Continuous Glucose Monitoring (CGM) / Real-Time Flash Glucose Scanning (FGS) in Type 1 Diabetes Mellitus in Children and Young People Under 18 Years

A Practical Approach to the Management of Continuous Glucose Monitoring (CGM) / Real-Time Flash Glucose Scanning (FGS) in Type 1 Diabetes Mellitus in Children and Young People Under 18 Years 1 Version 2, April 2017 Review 2020 Authors: ACDC Guideline Development Group N Wright, SM Ng, JC Agwu, P Adolfsson, J Drew, J Pemberton, M Kershaw, S Bissell, C Moudiotis, F Regan, C Gardner, A Astle, A Adams, G Adams, P Manning, A Timmis, A Soni, E Williams ssociation of Children’s Diabetes Clinicians (...) Clinicians FOR STAFF Healthcare professionals involved in care of children and young people with Type 1 Diabetes Mellitus PATIENTS Children and young people with diabetes mellitus This guideline is intended for use in managing continuous glucose monitoring (CGM) or real-time flash glucose scanning (FGS) for all children and young people under 18 years with Type 1 diabetes mellitus. Table of Contents Introduction 2 Overview of Pertinent NICE guidance 3 Devices Available for CGM and FGS 6 Section 1

2017 British Society for Paediatric Endocrinology and Diabetes

73. Pancreas Islet Transplantation for Patients With Type 1 Diabetes Mellitus

Pancreas Islet Transplantation for Patients With Type 1 Diabetes Mellitus Pancreas Islet Transplantation for Patients With Type 1 Diabetes Mellitus: OHTAC Recommendation HEALTH QUALITY ONTARIO ONTARIO HEALTH TECHNOLOGY ADVISORY COMMITTEE RECOMMENDATIONS • OHTAC recommends that pancreas islet cell transplantation be publicly funded as a treatment option for eligible adults with type 1 diabetes mellitus who have frequent episodes of hypoglycemic unawareness and/or uncontrollable diabetes despite (...) optimal medical therapy BACKGROUND Diabetes mellitus is a chronic condition characterized by high blood glucose levels. Type 1 diabetes mellitus, which affects a small proportion of patients with diabetes, is a result of autoimmune destruction of the pancreatic beta (ß) cells causing severe insulin deficiency. Patients with type 1 diabetes require lifelong insulin therapy to control their blood glucose levels. However, despite optimal insulin treatment, a very small proportion of patients (< 1%) still

2015 Health Quality Ontario

74. Association of protein tyrosine phosphatase non-receptor type 22 gene functional variant C1858T, HLA-DQ/DR genotypes and autoantibodies with susceptibility to type-1 diabetes mellitus in Kuwaiti Arabs. Full Text available with Trip Pro

Association of protein tyrosine phosphatase non-receptor type 22 gene functional variant C1858T, HLA-DQ/DR genotypes and autoantibodies with susceptibility to type-1 diabetes mellitus in Kuwaiti Arabs. The incidence of type-1 Diabetes Mellitus (T1DM) has increased steadily in Kuwait during recent years and it is now considered amongst the high-incidence countries. An interaction between susceptibility genes, immune system mediators and environmental factors predispose susceptible individuals (...) to T1DM. We have determined the prevalence of protein tyrosine phosphatase non-receptor type 22 (PTPN22) gene functional variant (C1858T; R620W, rs2476601), HLA-DQ and DR alleles and three autoantibodies in Kuwaiti children with T1DM to evaluate their impact on genetic predisposition of the disease. This study included 253 Kuwaiti children with T1DM and 214 ethnically matched controls. The genotypes of PTPN22 gene functional variant C1858T (R620W; rs2476601) were detected by PCR-RFLP method

2018 PLoS ONE

75. Insulin pumps for people with Type 1 Diabetes

with type 1 diabetes mellitus: o who use multiple daily injections of insulin (MDI) to achieve target HbA1c but result in the person experiencing disabling hypoglycaemia, where disabling hypoglycaemia is defined as the repeated and unpredictable occurrence of hypoglycaemia that results in persistent anxiety about recurrence and is associated with a significant adverse effect on quality of life (QoL); or o who have unacceptably high HbA1c (i.e. at 8.5% or above) on MDI despite a high level of care, where (...) Driving better decision-making in healthcare Factors considered to inform the recommendations for subsidy Technology evaluation 1.1 The MOH MTAC (“the Committee”) considered evidence presented for the evaluation of continuous subcutaneous insulin infusion therapy (CSII) for the treatment of people with type 1 diabetes mellitus (T1DM). The evaluation was conducted in consultation with clinical experts from the public healthcare institutions. Available clinical and economic evidence for CSII

2020 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

76. ABCD position statement on standards of care for management of adults with type 1 diabetes

is also available which includes a short summary of the recommendations from each section. The sections on inpatient care and management of diabetic emergencies are particularly relevant today. We are grateful to all the contributors. Discipline: Diabetes Clinical taxonomy: Type 1 diabetes mellitus Resource taxonomy: Guidelines Position Paper Information for HCPs Follow Us Address for correspondence: ABCD (Diabetes Care) Ltd, Miria House, 1683b High Street, Knowle, Solihull, West Midlands, B93 0LL (...) ABCD position statement on standards of care for management of adults with type 1 diabetes Standards of Care for Management of Adults with Type 1 Diabetes | ABCD (Diabetes Care) Ltd You are here: Standards of Care for Management of Adults with Type 1 Diabetes 2020 ABCD Standards of care for the management of adults with type 1 diabetes provides comprehensive standards for units providing care to people with type 1 diabetes and is intended as a resource for specialist teams. A summary document

2020 Association of British Clinical Diabetologists

77. Web-based intervention for depressive symptoms in adults with types 1 and 2 diabetes mellitus: a health economic evaluation Full Text available with Trip Pro

Web-based intervention for depressive symptoms in adults with types 1 and 2 diabetes mellitus: a health economic evaluation Web-based interventions are effective in reducing depression. However, the evidence for the cost-effectiveness of these interventions is scarce.AimsThe aim is to assess the cost-effectiveness of a web-based intervention (GET.ON M.E.D.) for individuals with diabetes and comorbid depression compared with an active control group receiving web-based psychoeducation.We (...) -effective.This web-based intervention for individuals with diabetes and comorbid depression demonstrated a high probability of being cost-effective compared with an active control group.Declaration of interestS.N., D.D.E., D.L., M.B. and B.F. are stakeholders of the Institute for Online Health Trainings, which aims to transfer scientific knowledge related to this research into routine healthcare.

2018 EvidenceUpdates

78. Perioperative Management of Pediatric Patients With Type 1 Diabetes Mellitus, Updated Recommendations for Anesthesiologists. (Abstract)

Perioperative Management of Pediatric Patients With Type 1 Diabetes Mellitus, Updated Recommendations for Anesthesiologists. Approximately 1 of every 300 children in the United States has type 1 diabetes mellitus (T1D), and these patients may require anesthetics for a variety of procedures. Perioperative coordination is complex, and attention to perioperative fasting, appropriate insulin administration, and management of hypo- and hyperglycemia, as well as other metabolic abnormalities (...) , is required. Management decisions may be impacted by the patient's baseline glycemic control and home insulin regimen, the type of procedure being performed, and expected postoperative recovery. If possible, preoperative planning with input from the patient's endocrinologist is considered best practice. A multi-institutional working group was formed by the Society for Pediatric Anesthesia Quality and Safety Committee to review current guidelines in the endocrinology and anesthesia literature and provide

2020 Anesthesia and Analgesia

79. Incidence trend of type 1 diabetes mellitus in Serbia. Full Text available with Trip Pro

Incidence trend of type 1 diabetes mellitus in Serbia. The incidence of type 1 diabetes mellitus (T1DM) increased worldwide. The objective of the paper was to compare the incidence trend of T1DM in children and adolescents aged 0-19 and in adults under 30 years of age in Serbia from 2006 to 2017. Additional aim was to compare incidence rates of T1DM and type 2 diabetes mellitus (T2DM) among adults aged 20-24 and 25-29 years of age.Trends and annual percentage change (APC) of the incidence rate

2020 BMC Endocrine Disorders

80. Factors influencing blood pressure and microalbuminuria in children with type 1 diabetes mellitus: salt or sugar? (Abstract)

Factors influencing blood pressure and microalbuminuria in children with type 1 diabetes mellitus: salt or sugar? The aim of the study is to identify the effect of salt intake and diabetes itself on blood pressure (BP) profile and microalbuminuria in children with type one diabetes mellitus (T1DM). Our hypothesis is that higher amount of salt consumption and/or hyperglycemia may impair blood pressure pattern in children with T1DM.This cross-sectional study included 84 children and adolescents (...) with T1DM (62% females, age 13.9 ± 3.2 years, disease duration 7.3 ± 3.1 years, 43% poorly controlled diabetes) and 54 aged- and sex-matched healthy children with an adequately collected 24-h urine samples. Urine sodium, creatinine, and microalbumin were measured and salt intake was assessed on the basis of sodium excretion in 24-h urine. Blood pressure profile of the children with T1DM was evaluated with 24-h ambulatory blood pressure monitoring.Compared to the children with well-controlled diabetes

2020 Pediatric Nephrology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>